Published in J Virol on April 01, 2006
Viral membrane fusion. Nat Struct Mol Biol (2008) 8.54
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature (2011) 5.68
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol (2008) 5.26
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature (2008) 5.24
Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature (2011) 3.66
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog (2010) 2.60
Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog (2010) 2.60
Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol (2007) 2.16
The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol (2009) 2.15
T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A (2011) 2.12
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog (2012) 2.09
Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J (2012) 2.08
Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J Virol (2007) 1.93
Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology (2008) 1.89
A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J Virol (2010) 1.87
A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol (2011) 1.84
Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A (2009) 1.83
Viral entry mechanisms: the increasing diversity of paramyxovirus entry. FEBS J (2009) 1.82
The cell biology of receptor-mediated virus entry. J Cell Biol (2011) 1.75
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med (2013) 1.62
Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J Virol (2010) 1.62
Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs (2013) 1.57
Ebolavirus glycoprotein structure and mechanism of entry. Future Virol (2009) 1.56
Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J Virol (2011) 1.46
A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses. Science (2016) 1.45
Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol (2010) 1.44
Proteolytic cleavage of VP1-2 is required for release of herpes simplex virus 1 DNA into the nucleus. J Virol (2008) 1.44
Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS Pathog (2015) 1.41
The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus. J Virol (2010) 1.36
Ebola Virus Glycoprotein with Increased Infectivity Dominated the 2013-2016 Epidemic. Cell (2016) 1.35
Forty-five years of Marburg virus research. Viruses (2012) 1.34
Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One (2013) 1.29
Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry. J Virol (2013) 1.29
Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr Opin Struct Biol (2009) 1.28
Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc Natl Acad Sci U S A (2009) 1.26
Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion. PLoS Negl Trop Dis (2011) 1.23
Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein. Virology (2011) 1.22
The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology (2011) 1.22
Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J Virol (2012) 1.21
Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. J Virol (2011) 1.21
Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2. Proc Natl Acad Sci U S A (2011) 1.20
Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors. J Virol (2009) 1.20
Filovirus tropism: cellular molecules for viral entry. Front Microbiol (2012) 1.18
Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell (2015) 1.18
Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol (2009) 1.16
Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets. Protein Sci (2014) 1.16
Structural basis for differential neutralization of ebolaviruses. Viruses (2012) 1.15
Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. J Virol (2009) 1.15
Identification of a small-molecule entry inhibitor for filoviruses. J Virol (2011) 1.14
Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry. Proc Natl Acad Sci U S A (2010) 1.14
Filovirus entry into cells - new insights. Curr Opin Virol (2012) 1.14
Cholesterol dependence of varicella-zoster virion entry into target cells. J Virol (2007) 1.10
Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology (2010) 1.09
The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR. J Virol (2006) 1.09
A new player in the puzzle of filovirus entry. Nat Rev Microbiol (2012) 1.08
Camouflage and misdirection: the full-on assault of ebola virus disease. Cell (2014) 1.07
Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. MBio (2014) 1.05
Cell adhesion promotes Ebola virus envelope glycoprotein-mediated binding and infection. J Virol (2008) 1.05
Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism. Virology (2007) 1.05
Two-step conformational changes in a coronavirus envelope glycoprotein mediated by receptor binding and proteolysis. J Virol (2009) 1.05
Expression of Ebolavirus glycoprotein on the target cells enhances viral entry. Virol J (2009) 1.04
Filovirus entry: a novelty in the viral fusion world. Viruses (2012) 1.03
A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. Mol Pharmacol (2010) 1.03
Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step. J Virol (2014) 1.02
Designed protein mimics of the Ebola virus glycoprotein GP2 α-helical bundle: stability and pH effects. Protein Sci (2011) 1.02
Cathepsin B & L are not required for ebola virus replication. PLoS Negl Trop Dis (2012) 1.02
Host cell cathepsins potentiate Moloney murine leukemia virus infection. J Virol (2007) 1.02
Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. J Biol Chem (2011) 1.01
Intracellular events and cell fate in filovirus infection. Viruses (2011) 1.01
An update on the use of antibodies against the filoviruses. Immunotherapy (2013) 1.01
Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry. J Virol (2011) 1.01
Pre-fusion structure of a human coronavirus spike protein. Nature (2016) 1.01
Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies. J Virol (2015) 1.00
Activation of the Nipah virus fusion protein in MDCK cells is mediated by cathepsin B within the endosome-recycling compartment. J Virol (2012) 1.00
Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. J Virol (2007) 1.00
Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis (2011) 0.99
Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography. J Virol (2014) 0.99
Differential role for low pH and cathepsin-mediated cleavage of the viral spike protein during entry of serotype II feline coronaviruses. Vet Microbiol (2008) 0.99
Cysteines flanking the internal fusion peptide are required for the avian sarcoma/leukosis virus glycoprotein to mediate the lipid mixing stage of fusion with high efficiency. J Virol (2008) 0.99
Different potential of C-type lectin-mediated entry between Marburg virus strains. J Virol (2010) 0.98
Jaagsiekte sheep retrovirus utilizes a pH-dependent endocytosis pathway for entry. J Virol (2007) 0.98
Crystal structure of the Marburg virus GP2 core domain in its postfusion conformation. Biochemistry (2012) 0.98
Marburg virus glycoprotein GP2: pH-dependent stability of the ectodomain α-helical bundle. Biochemistry (2012) 0.97
Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein. Chembiochem (2012) 0.97
Niemann-Pick C1 (NPC1)/NPC1-like1 chimeras define sequences critical for NPC1's function as a flovirus entry receptor. Viruses (2012) 0.96
Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry. J Med Chem (2011) 0.95
Synchronized retrovirus fusion in cells expressing alternative receptor isoforms releases the viral core into distinct sub-cellular compartments. PLoS Pathog (2012) 0.94
Discovery of an antibody for pan-ebolavirus therapy. Sci Rep (2016) 0.93
Receptor binding and low pH coactivate oncogenic retrovirus envelope-mediated fusion. J Virol (2009) 0.93
Ebola virus entry: a curious and complex series of events. PLoS Pathog (2015) 0.93
Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Res (2015) 0.92
The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge. Antiviral Res (2012) 0.92
Equine infectious anemia virus entry occurs through clathrin-mediated endocytosis. J Virol (2007) 0.92
Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science (2016) 0.92
Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature (2016) 0.92
Enzootic nasal tumor virus envelope requires a very acidic pH for fusion activation and infection. J Virol (2008) 0.91
Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science (2005) 7.07
A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A (1997) 6.86
Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein. Cell (2000) 4.88
The many mechanisms of viral membrane fusion proteins. Curr Top Microbiol Immunol (2005) 4.19
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A (2005) 4.07
Fusion of Semliki forest virus with the plasma membrane can be induced by low pH. J Cell Biol (1980) 3.47
Covalent modifications of the ebola virus glycoprotein. J Virol (2002) 2.84
Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells. J Biol Chem (2002) 2.76
Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol (2002) 2.58
Comprehensive analysis of ebola virus GP1 in viral entry. J Virol (2005) 2.56
Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). Proc Natl Acad Sci U S A (2000) 2.40
The lysosomal cysteine proteases. Annu Rev Biophys Biomol Struct (1999) 2.34
Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function. J Virol (1999) 2.32
Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein. J Virol (2005) 2.25
Isomerization of the intersubunit disulphide-bond in Env controls retrovirus fusion. EMBO J (2003) 1.93
Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci U S A (2005) 1.85
Sequential roles of receptor binding and low pH in forming prehairpin and hairpin conformations of a retroviral envelope glycoprotein. J Virol (2004) 1.62
Cathepsin S supports acid-independent infection by some reoviruses. J Biol Chem (2003) 1.23
Sites and determinants of early cleavages in the proteolytic processing pathway of reovirus surface protein sigma3. J Virol (2002) 1.17
Kinetic analyses of the surface-transmembrane disulfide bond isomerization-controlled fusion activation pathway in Moloney murine leukemia virus. J Virol (2005) 1.12
CAS/Crk signalling mediates uptake of Yersinia into human epithelial cells. Cell Microbiol (2000) 1.08
Neutrophil elastase, an acid-independent serine protease, facilitates reovirus uncoating and infection in U937 promonocyte cells. Virol J (2005) 1.05
Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol (2013) 1.21
Soluble receptor potentiates receptor-independent infection by murine coronavirus. J Virol (2002) 1.17
Entry from the cell surface of severe acute respiratory syndrome coronavirus with cleaved S protein as revealed by pseudotype virus bearing cleaved S protein. J Virol (2008) 1.16
Role of proteases in the release of porcine epidemic diarrhea virus from infected cells. J Virol (2011) 1.14
Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol (2005) 1.09
Protease-mediated entry via the endosome of human coronavirus 229E. J Virol (2008) 1.09
Detection of bat coronaviruses from Miniopterus fuliginosus in Japan. Virus Genes (2011) 1.08
Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol (2012) 1.04
Enacyloxins are products of an unusual hybrid modular polyketide synthase encoded by a cryptic Burkholderia ambifaria Genomic Island. Chem Biol (2011) 0.98
Stress kinase p38 mediates EGFR transactivation by hyperosmolar concentrations of sorbitol. J Cell Physiol (2002) 0.96
Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP). Virol J (2014) 0.92
Impact of Pseudomonas aeruginosa genomic instability on the application of typing methods for chronic cystic fibrosis infections. J Clin Microbiol (2010) 0.89
TMPRSS2 is an activating protease for respiratory parainfluenza viruses. J Virol (2013) 0.86
Recombinant nucleocapsid protein-based IgG enzyme-linked immunosorbent assay for the serological diagnosis of SARS. J Virol Methods (2005) 0.84
N-terminus oligomerization regulates the function of cardiac ryanodine receptors. J Cell Sci (2013) 0.83
Characterization of a variant virus from ascitic fluid of subacute granulomatous serositis in interferon-gamma-deficient C57BL/6 mice persistently infected with murine coronavirus strain JHM. Viral Immunol (2010) 0.83
Mutation in the cytoplasmic retrieval signal of porcine epidemic diarrhea virus spike (S) protein is responsible for enhanced fusion activity. Virus Res (2011) 0.82
Differences in neutralizing antigenicity between laboratory and clinical isolates of HCoV-229E isolated in Japan in 2004-2008 depend on the S1 region sequence of the spike protein. J Gen Virol (2012) 0.81
Expression of the HPV11 E2 gene in transgenic mice does not result in alterations of the phenotypic pattern. Transgenic Res (2007) 0.81
Receptor-independent infection of murine coronavirus: analysis by spinoculation. J Virol (2006) 0.81
Hyperosmotic stress induces phosphorylation of cytosolic phospholipase A(2) in HaCaT cells by an epidermal growth factor receptor-mediated process. Cell Signal (2002) 0.79
Pseudotyped vesicular stomatitis virus for functional analysis of SARS coronavirus spike protein. Adv Exp Med Biol (2006) 0.77
Two palmitylated cysteine residues of the severe acute respiratory syndrome coronavirus spike (S) protein are critical for S incorporation into virus-like particles, but not for M-S co-localization. J Gen Virol (2012) 0.76
Middle East respiratory syndrome coronavirus infection not found in camels in Japan. Jpn J Infect Dis (2015) 0.76
Receptor-independent infection by mutant viruses newly isolated from the neuropathogenic mouse hepatitis virus srr7 detected through a combination of spinoculation and ultraviolet radiation. Jpn J Infect Dis (2011) 0.75
Spongiform degeneration induced by neuropathogenic murine coronavirus infection. Pathol Int (2011) 0.75
Increased replication of respiratory syncytial virus in the presence of cytokeratin 8 and 18. J Med Virol (2012) 0.75
[Cell entry mechanisms of coronaviruses]. Uirusu (2009) 0.75
Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease. J Med Virol (2014) 0.75